K-ras mutations correlate with atypical cytology and elevated CEA levels in pancreatic cystic neoplasms.
BACKGROUND
Benign pancreatic cystic neoplasms are important precursors to pancreatic adenocarcinoma, and offer the opportunity to prevent cancer. Conversely, prevention only occurs with surgical resection associated with significant morbidity and mortality, while the natural history of small cystic neoplasms is a slow and uncertain progression to malignancy. Markers that predict progression to malignancy are needed. Cyst fluid DNA analysis including K-ras mutations may predict more aggressive natural history of pancreatic cystic neoplasms.


METHODS
Sixty patients with pancreatic cysts measuring less than 3 cm without solid component or pancreatic ductal dilation underwent EUS with fine needle aspiration. Nine had surgical resection. Cyst fluid was tested for cytology, CEA levels, and DNA analysis including K-ras mutations, and eight loss of heterozygosity mutations. Mutations were correlated with findings of atypia and CEA levels.


RESULTS
Cyst fluid K-ras mutation was found in 30% of patients. Patients with mutated K-ras were more likely to have atypia on cytology or pathology (39 vs. 14%) and higher CEA (median 591 vs. 42) compared to wild-type K-ras. K-ras mutants were more likely to have two or more loss of heterozygosity mutations. Loss of heterozygosity mutations did not correlate with atypia or CEA levels.


CONCLUSIONS
Cyst fluid K-ras mutation correlates with other markers of aggressive cyst behavior. EUS with cyst DNA analysis may alter management of smaller pancreatic cysts when surgery might otherwise be deferred. Further studies of cyst fluid DNA and long-term outcomes are needed.
Vanderbilt University, Nashville, TN, USA, hmertz@comcast.net.
Howard
H
Mertz
D000230:Adenocarcinoma / Q000235:genetics* / Q000601:surgery; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D044963:Biopsy, Fine-Needle; D002272:Carcinoembryonic Antigen / Q000097:blood*; D020420:Cyst Fluid / Q000737:chemistry; D011905:Genes, ras; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D010181:Pancreatic Cyst / Q000097:blood* / Q000235:genetics* / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000601:surgery; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen
Am J Gastroenterol. 2003 Jul;98(7):1516-24
12873573
Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500
9351717
Am J Surg Pathol. 2004 Aug;28(8):977-87
15252303
Clin Gastroenterol Hepatol. 2006 Apr;4(4):460-8
16616351
Gastrointest Endosc. 2009 May;69(6):1095-102
19152896
N Engl J Med. 1988 Sep 1;319(9):525-32
2841597
Clin Gastroenterol Hepatol. 2005 Oct;3(10):967-73
16234041
Gastrointest Endosc. 2005 Sep;62(3):390-1
16111957
Gastrointest Endosc. 2006 Nov;64(5):697-702
17055859
Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6
19501586
Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10
17631133
Clin Gastroenterol Hepatol. 2007 Apr;5(4):489-95
17350894
J Pathol. 2003 Apr;199(4):453-61
12635136
Gastroenterology. 2004 May;126(5):1330-6
15131794
Cancer Res. 2007 May 15;67(10):4671-8
17510393
Gastrointest Endosc. 2005 Sep;62(3):383-9
16111956
Diagn Cytopathol. 2006 Sep;34(9):605-8
16900481
Pancreatology. 2006;6(1-2):17-32
16327281
Acta Cytol. 1991 Jul-Aug;35(4):456-63
1718115
Am J Gastroenterol. 2007 Oct;102(10):2339-49
17764489
J Hepatobiliary Pancreat Surg. 2002;9(1):76-85
12021900